The S.E.C. alleged shortcomings in research said to support the drug, and its developer agreed to a $40 million settlement.

Scientists say they have achieved a "first" in the development of drugs to treat Alzheimer's disease. In a study published in ...

Pulses of light and sound seem to have beneficial effects. But some argue it is too soon to market experimental devices.

Patients tolerated synthetic THC (dronabinol) well, without the adverse effects commonly associated with existing Alzheimer's ...

CADASIL is a brain disease involving genetic mutations, stroke, and dementia. Learn about symptom progression and ongoing ...

An FDA-approved synthetic THC significantly reduces agitation in Alzheimer's patients, improving treatment outcomes and ...

An FDA-approved synthetic version of THC (the main ingredient in cannabis) reduces agitation in patients with Alzheimer's ...

Shares of Cassava Sciences fell 10% in post-market trading on Thursday after the U.S. Securities and Exchange Commission ...

“This research is taking promising steps towards a new one-of-a-kind therapy which targets tau, a damaging protein in the ...

An investigation has uncovered alarming issues including increased mortality rates, absent safety records, dubious efficacy, ...

The Securities and Exchange Commission today announced Cassava Sciences, Inc., its founder and former CEO, Remi Barbier, and ...

Managing dementia in the complex landscape of neurological disorders stands out as a formidable challenge, affecting millions ...